Assessment of JC virus DNA in blood and urine from natalizumab‐treated patients

Rudick, Richard A.; O’Connor, Paul; Polman, Chris H.; Goodman, Andrew; Ray, Soma; Griffith, Nancy M.; Jurgensen, Stéphanie; Gorelik, Leonid; Forrestal, Fiona; Sandrock, Alfred; Goelz, Susan

doi:10.1002/ana.22107

Cited by 98 publications

(62 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients who are found to be JCV-seronegative should be followed for seroconversion repeatedly during immunosuppressive treatment. By contrast, several studies have demonstrated that screening for JCV DNA in blood, CSF, or urine does not enhance the ability to predict development of PML 29,30 .…”

Section: Rheumatologymentioning

confidence: 94%

Progressive Multifocal Leukoencephalopathy in a Patient with Polymyositis: Case Report and Literature Review

Dastmalchi¹,

Laki²,

Lundberg³

et al. 2012

J Rheumatol

View full text Add to dashboard Cite

Section: Rheumatologymentioning

confidence: 94%

Progressive Multifocal Leukoencephalopathy in a Patient with Polymyositis: Case Report and Literature Review

Dastmalchi¹,

Laki²,

Lundberg³

et al. 2012

J Rheumatol

View full text Add to dashboard Cite

“…2,4,5 In one of the largest studies, 5 urinary JCV-DNA could not be detected in 1 of 3 patients who subsequently developed PML; urinary JCV excretion was detected frequently and did not increase during natalizumab treatment. Thus, predictive values of either positive or negative tests appear to be low.…”

Section: Megan Alcauskas MD and Robert C Griggs Mdmentioning

confidence: 97%

“…Thus, predictive values of either positive or negative tests appear to be low. 5 Using urinary JCV-DNA analysis, a false-negative rate of the 2-step anti-JCVantibody ELISA of approximately 2.7% can be calculated. 4 Due to lack of biomaterial we were not able to determine the rate of false-negative findings of anti-JCV serology in our cohort.…”

Section: Megan Alcauskas MD and Robert C Griggs Mdmentioning

confidence: 99%

Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort

Zahednasab¹,

Trampe²,

Stroet³

et al. 2012

Neurology

View full text Add to dashboard Cite

“…Following initial infection, the virus persists in kidneys and in other tissues, including the brain. In immunologically normal patients this JCV persistence only results in recurrent episodes of asymptomatic viruria [184].…”

Section: Progressive Multifocal Leukoencephalopathymentioning

confidence: 99%

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

et al. 2016

View full text Add to dashboard Cite

Neurological involvement is relatively common in the majority of systemic autoimmune diseases and may lead to severe morbidity and mortality, if not promptly treated. Treatment options vary greatly, depending on the underlying systemic pathophysiology and the associated neurological symptoms. Selecting the appropriate therapeutic scheme is further complicated by the lack of definite therapeutic guidelines, the necessity to differentiate primary neurological syndromes from those related to the underlying systemic disease, and to sort out adverse neurological manifestations caused by immunosuppressants or the biological agents used to treat the primary disease. Immunotherapy is a sine qua non for treating most, if not all, neurological conditions presenting in the context of systemic autoimmunity. Specific agents include classical immune modulators such as corticosteroids, cyclophosphamide, intravenous immunoglobulin, and plasma exchange, as well as numerous biological therapies, for example antitumor necrosis factor agents and monoclonal antibodies that target various immune pathways such as B cells, cytokines, and co-stimulatory molecules. However, experience regarding the use of these agents in neurological complications of systemic diseases is mainly empirical or based on small uncontrolled studies and case series. The aim of this review is to present the state-of-the-art therapies applied in various neurological manifestations encountered in the context of systemic autoimmune diseases; evaluate all treatment options on the basis of existing guidelines; and compliment these data with our personal experience derived from a large number of patients.

show abstract

Assessment of JC virus DNA in blood and urine from natalizumab‐treated patients

Abstract: Measuring JCV DNA in blood or urine with currently available methods is unlikely to be useful for predicting PML risk in natalizumab-treated MS patients.

Cited by 98 publications

References 15 publications

Progressive Multifocal Leukoencephalopathy in a Patient with Polymyositis: Case Report and Literature Review

Progressive Multifocal Leukoencephalopathy in a Patient with Polymyositis: Case Report and Literature Review

Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

Contact Info

Product

Resources

About